Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Aleniglipron

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Gasherbrum Bio, Inc · Phase 3 · Recruiting · Enrollment 3600

NCT07654361

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
aleniglipron Arm 1n/rn/rn/rn/r
aleniglipron Arm 2n/rn/rn/rn/r
aleniglipron Arm 3n/rn/rn/rn/r
Placebo Arm 4n/rn/rn/rn/r

Not shown

  • aleniglipron Arm 1: endpoint not reported
  • aleniglipron Arm 2: endpoint not reported
  • aleniglipron Arm 3: endpoint not reported
  • Placebo Arm 4: endpoint not reported